Find out how oral GLP-1 RAs will affect treatment plans
An ongoing barrier to treatment with GLP-1 receptor agonists is their injectable nature. A novel oral formulation of a GLP-1 RA is being evaluated in a series of phase III trials. However, a number of questions remain:
- How effective is this oral formulation compared to injectable GLP-1 RAs?
- Does the formulation affect the side effect profile of the GLP-1 RA?
- Are there any specific dosing requirements for this oral formulation?
Don't miss our next journal club on Thursday 28 February with Dr Antia Varoda. Sign up to this free, CME-accredited webinar to reserve your slot.